Triazolyl phenyl benzenesulfonamides
Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
1. A compound selected from the group consisting of (S)-4-tert-butyl-N-(4-chloro-2-(4-(pyrrolidin-3-yl)-4H-1,2,4- triazol-3-yl)phenyl)benzenesulfonamide and (R)-4-tert-butyl-N-(4-chloro-2-(4- (pyrrolidin-3-yl)-4H-1,2,4-triazol-3-yl)phenyl)benzenesulfonamide; or a salt thereof.
2. A compound of the formula:
or a salt thereof.
3. A composition comprising a pharmaceutically acceptable carrier and a compound of claim 2 .
4. A compound of the formula: